This Japanese company has an oligonucleotide synthesis technology which was developed based on their proprietary raw materials.
The advantage is that they resolved many issues the conventional oligonucleotide synthesis methods had.
Oligonucleotide synthesis applies in both the pharma industry and academia research sectors.
The company seeks EU partners who can help them represent, distribute, and manufacture products produced with this synthesis technology.
Please see the company pdf for more details.
The EU-Japan Centre currently produces 5 newsletters :